How Do You Spell AMPHOTERICIN B COLLOIDAL DISPERSION?

Pronunciation: [ˈamfə͡ʊtɹˌɪsɪn bˈiː kˈɒlɔ͡ɪdə͡l dɪspˈɜːʃən] (IPA)

Amphotericin B Colloidal Dispersion is a medication used to treat fungal infections. The phonetic transcription of this word is /æmfoʊtɛrɪsɪn b kəˈlɔɪdəl dɪˈspɜrʒən/. The word 'Amphotericin' is pronounced as 'am-foh-ter-uh-sin', whereas 'Colloidal' is pronounced as 'kuh-loid-l'. The spelling of this word is complex as it combines the names of the medication and the dispersing agent. This drug is mainly used in hospital settings as it requires careful administration due to its potential toxicity.

AMPHOTERICIN B COLLOIDAL DISPERSION Meaning and Definition

1. Amphotericin B Colloidal Dispersion is a pharmaceutical formulation that contains the antifungal drug called Amphotericin B.

   Amphotericin B is an amphiphilic polyene macrolide antibiotic produced by strains of the bacterium Streptomyces nodosus. It exhibits potent antifungal activity against a wide range of pathogenic fungi, making it a valuable option for the treatment of serious invasive fungal infections. However, Amphotericin B is known to have poor water solubility and can cause significant toxicity when administered systemically.

   To overcome these limitations, Amphotericin B Colloidal Dispersion is developed by suspending Amphotericin B particles in an aqueous colloidal solution. This formulation improves the drug's solubility, enhancing its bioavailability and reducing the risk of toxicity. The colloidal dispersion consists of microscopic particles of Amphotericin B, typically encapsulated in a liposomal or lipid complex structure, which enhances drug uptake by target cells.

   The colloidal dispersion formulation allows for a controlled release of the drug, resulting in sustained therapeutic levels within the body. It is administered intravenously, either directly or after dilution, under the supervision of healthcare professionals.

   Amphotericin B Colloidal Dispersion is primarily used in the treatment of severe systemic fungal infections, such as invasive aspergillosis, cryptococcal meningitis, and candidemia. It is often considered as a second-line therapy when other antifungal agents have proven ineffective or are contraindicated. Close monitoring of patients' renal and hepatic functions is essential due to the potential nephrotoxicity and hepatotoxicity associated with Amphotericin B therapy.

Common Misspellings for AMPHOTERICIN B COLLOIDAL DISPERSION

• zmphotericin b colloidal dispersion
• smphotericin b colloidal dispersion
• wmphotericin b colloidal dispersion
• qmphotericin b colloidal dispersion
• anphotericin b colloidal dispersion
• akphotericin b colloidal dispersion
• ajphotericin b colloidal dispersion
• amohotericin b colloidal dispersion
• amlhotericin b colloidal dispersion
• am-hotericin b colloidal dispersion
• am0hotericin b colloidal dispersion
• ampgotericin b colloidal dispersion
• ampbotericin b colloidal dispersion
• ampnotericin b colloidal dispersion
• ampjotericin b colloidal dispersion
• ampuotericin b colloidal dispersion
• ampyotericin b colloidal dispersion
• amphitericin b colloidal dispersion
• amphktericin b colloidal dispersion
• amphltericin b colloidal dispersion